FDMT Research and Charts

FDMT - 4D Molecular Therapeutics Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-04-04)

Last 2.77	Change ⇓ -0.12 (-4.15%)	Volume 559,862
	Open 2.82	High 2.85	Low 2.67

8EMA (Daily) 3.26	40EMA (Daily) 4.17	50EMA (Daily) 4.42	STO (Daily) 10.513	MACD Hist (Daily) -0.141
8EMA (Weekly) 4.012	40EMA (Weekly) 9.05	50EMA (Weekly) 10.28	STO (Weekly) 6.274	MACD Hist (Weekly) 0.296


Company Profile
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.